MDLNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Medline Inc.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$35.19−0.77 (-2.14%)
Close on Oct 19, 2026
- Market cap
- $30.29B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2022 to 2025
Gross margin
26.4%
Operating margin
7.8%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +11.5% | – | – | – | |
| Gross profit | +7.8% | – | – | – | |
| Operating income | +3.1% | – | – | – | |
| Free cash flow | -8.3% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2022 | FY2022 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 4.29 | |
| Net debt to EBITDA | – | – | 3.30× | |
| Interest coverage | – | – | 2.3× | |
| Capex to revenue | – | – | 1.6% |
Cash use needs five years of cash flow figures
Medline does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$1.16B
- Cash generatingOperating cash flow above zero$1.74B
- Return on assets improvedROA up on the prior year– → 3.2%
- Earnings backed by cashOperating cash flow above net income$1.74B vs $1.16B
- Less leverageLong-term debt to assets fell45.6% → 32.4%
- Better liquidityCurrent ratio rose3.39 → 4.29
- No dilutionShare count did not rise– → 810M
- Gross margin improvedGross margin up on the prior year27.35% → 26.44%
- More efficientAsset turnover rose– → 0.79